We are live on ! Find out more
OMIC

Singular Genomics Systems, Inc. Common Stock

Delisted

OMIC was delisted on the 20th of February, 2025.

62 hedge funds and large institutions have $27.3M invested in Singular Genomics Systems, Inc. Common Stock in 2023 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 16 increasing their positions, 21 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

125% more call options, than puts

Call options by funds: $27K | Put options by funds: $12K

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

6% less funds holding

Funds holding: 6662 (-4)

21% less first-time investments, than exits

New positions opened: 15 | Existing positions closed: 19

24% less repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 21

38% less capital invested

Capital invested by funds: $43.8M → $27.3M (-$16.6M)

Holders
62
Holders Change
-4
Holders Change %
-6.06%
% of All Funds
0.97%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
15
Increased
16
Reduced
21
Closed
19
Calls
$27K
Puts
$12K
Net Calls
+$15K
Net Calls Change
-$24K
Name Holding Trade Value Shares
Change
Change in
Stake
MAM
26
Marquette Asset Management
Minnesota
$114K +$98.1K +3,347 +275%
Renaissance Technologies
27
Renaissance Technologies
New York
$91K +$85.2K +2,907 +388%
Susquehanna International Group
28
Susquehanna International Group
Pennsylvania
$89.7K +$24.9K +850 +31%
OMC
29
Old Mission Capital
Illinois
$78.9K +$92.8K +3,169 New
Qube Research & Technologies (QRT)
30
Qube Research & Technologies (QRT)
United Kingdom
$70.6K +$83.1K +2,836 New
Northern Trust
31
Northern Trust
Illinois
$66.7K -$397K -13,563 -84%
JP Morgan Chase
32
JP Morgan Chase
New York
$64.1K -$50.4K -1,719 -40%
GCP
33
GSA Capital Partners
United Kingdom
$62K -$137K -4,687 -65%
WC
34
Weil Company
California
$56.6K +$14.6K +500 +28%
Morgan Stanley
35
Morgan Stanley
New York
$54.2K -$19.1K -653 -23%
E
36
Ergoteles
New York
$46.3K +$36.2K +1,237 +199%
Jane Street
37
Jane Street
New York
$41.8K +$49.2K +1,678 New
D.E. Shaw & Co
38
D.E. Shaw & Co
New York
$33.8K +$6.5K +222 +20%
MSA
39
Marino Stram & Associates
Massachusetts
$33.2K +$29.3K +1,000 +300%
Citadel Advisors
40
Citadel Advisors
Florida
$23.5K +$21.3K +728 +335%
Cambridge Investment Research Advisors
41
Cambridge Investment Research Advisors
Iowa
$22K
Bank of New York Mellon
42
Bank of New York Mellon
New York
$21.2K -$140K -4,778 -85%
Charles Schwab
43
Charles Schwab
California
$19.5K -$124K -4,229 -84%
PMEF
44
Point72 Middle East FZE
United Arab Emirates
$16.2K +$19.1K +652 New
Deutsche Bank
45
Deutsche Bank
Germany
$16.2K -$22.6K -771 -54%
TRCT
46
Tower Research Capital (TRC)
New York
$15.7K +$8.14K +278 +79%
CAPTRUST Financial Advisors
47
CAPTRUST Financial Advisors
North Carolina
$13.4K +$820 +28 +5%
Bank of America
48
Bank of America
North Carolina
$12.5K -$40.9K -1,396 -74%
BRG
49
Bay Rivers Group
Virginia
$11.6K
Balyasny Asset Management
50
Balyasny Asset Management
Illinois
$11.5K +$13.6K +463 New

OMIC Hedge Fund Activity: Q2 2023 in Review

62 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in Singular Genomics Systems, Inc. Common Stock (OMIC) for Q2 2023, worth a combined $27.3M — down 38% from $43.8M a quarter earlier.

Sellers outnumbered buyers: 19 funds closed out of OMIC and 15 opened new positions — a net loss of 4 holders — while 21 trimmed existing stakes and 16 added.

The largest buyer was Millennium Management, opening a new position worth an estimated $840K. The largest seller was BlackRock, cutting an estimated $2.54M.

  • 62 institutional investors held Singular Genomics Systems, Inc. Common Stock (OMIC) as of Q2 2023, down from 66 in Q1 2023.
  • Funds reported $27.3M of Singular Genomics Systems, Inc. Common Stock stock for Q2 2023, down 38% quarter-over-quarter.
  • 15 funds opened new Singular Genomics Systems, Inc. Common Stock positions in Q2 2023 and 19 closed out, a net change of -4 holders.
  • The largest Singular Genomics Systems, Inc. Common Stock buyer in Q2 2023 was Millennium Management, an estimated $840K added.
  • The largest Singular Genomics Systems, Inc. Common Stock seller in Q2 2023 was BlackRock, an estimated $2.54M sold.

Based on aggregated 13F filings for Q2 2023.